Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.

Autor: Munusamy Ponnan S; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Swaminathan S; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Tiruvengadam K; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., K K V; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Cheedarla N; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Nesakumar M; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Kathirvel S; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Goyal R; International AIDS Vaccine Initiative, New Delhi, India., Singla N; International AIDS Vaccine Initiative, New Delhi, India., Mukherjee J; International AIDS Vaccine Initiative, New Delhi, India., Bergin P; IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom., T Kopycinski J; IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom., Gilmour J; IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom., Prasad Tripathy S; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India., Luke HE; National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2018 Aug 29; Vol. 13 (8), pp. e0203037. Date of Electronic Publication: 2018 Aug 29 (Print Publication: 2018).
DOI: 10.1371/journal.pone.0203037
Abstrakt: A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009 to test a subtype C prophylactic vaccine in a prime-boost regimen comprising of a DNA prime (ADVAX) and MVA (TBC-M4) boost. The trial demonstrated that the regimen was safe and well tolerated and resulted in enhancement of HIV-specific immune responses. Preliminary observations on vaccine-induced immune responses were limited to analysis of neutralizing antibodies and IFN-γ ELISPOT response. The present study involves a more detailed analysis of the nature of the vaccine-induced humoral immune response using specimens that were archived from the volunteers at the time of the trial. Interestingly, we found vaccine induced production of V1/V2 and V3 region-specific antibodies in a significant proportion of vaccinees. Variable region antibody levels correlated directly with the frequency of circulating T follicular helper cells (Tfh) and regulatory T cells (Treg). Our findings provide encouraging evidence to demonstrate the immunogenicity of the tested vaccine. Better insights into vaccine-induced immune responses can aid in informing future design of a successfulHIV-1 vaccine.
Competing Interests: None of the authors of this paper has any conflict of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje